Advanced

Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus

Nordmark, G; Bengtsson, Christine LU ; Larsson, A; Karlsson, FA; Sturfelt, Gunnar LU and Ronnblom, L (2005) In Autoimmunity 38(7). p.531-540
Abstract
The objective of this study was to evaluate the efficacy of low dose dehydroepiandrosterone (DHEA) on health-related quality of life (HRQOL) in glucocorticoid treated female patients with systemic lupus erythematosus (SLE). Forty one women (>= 5 mg prednisolone/day) were included in a double-blind, randomized, placebo-controlled study for 6 months where DHEA was given at 30 mg/20 mg (<= 45/>= 46 years) daily, or placebo, followed by 6 months open DHEA treatment to all patients. HRQOL was assessed at baseline, 6 and 12 months, using four validated questionnaires and the patients' partners completed a questionnaire assessing mood and behaviour at 6 months. DHEA treatment increased serum levels of sulphated DHEA from subnormal to... (More)
The objective of this study was to evaluate the efficacy of low dose dehydroepiandrosterone (DHEA) on health-related quality of life (HRQOL) in glucocorticoid treated female patients with systemic lupus erythematosus (SLE). Forty one women (>= 5 mg prednisolone/day) were included in a double-blind, randomized, placebo-controlled study for 6 months where DHEA was given at 30 mg/20 mg (<= 45/>= 46 years) daily, or placebo, followed by 6 months open DHEA treatment to all patients. HRQOL was assessed at baseline, 6 and 12 months, using four validated questionnaires and the patients' partners completed a questionnaire assessing mood and behaviour at 6 months. DHEA treatment increased serum levels of sulphated DHEA from subnormal to normal. The DHEA group improved in SF-36 "role emotional" and HSCL-56 total score (both p < 0.05). During open DHEA treatment, the former placebo group improved in SF-36 "mental health" (p < 0.05) with a tendency for improvement in HSCL-56 total score (p = 0.10). Both groups improved in McCoy's Sex Scale during active treatment (p < 0.05). DHEA replacement decreased high-density lipoprotein (HDL) cholesterol and increased insulin-like growth factor I (IGF-I) and haematocrit. There were no effects on bone density or disease activity and no serious adverse events. Side effects were mild. We conclude that low dose DHEA treatment improves HRQOL with regard to mental well-being and sexuality and can be offered to women with SLE where mental distress and/or impaired sexuality constitutes a problem. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
health-related quality of life, SLE, DHEA, glucocorticoid
in
Autoimmunity
volume
38
issue
7
pages
531 - 540
publisher
Taylor & Francis
external identifiers
  • wos:000233776800008
  • pmid:16373258
  • scopus:30844446256
ISSN
0891-6934
DOI
10.1080/08916930500285550
language
English
LU publication?
yes
id
05c863d7-4e9e-4145-89c5-0edece7cdd7a (old id 211224)
date added to LUP
2007-08-10 15:54:24
date last changed
2017-04-02 04:05:19
@article{05c863d7-4e9e-4145-89c5-0edece7cdd7a,
  abstract     = {The objective of this study was to evaluate the efficacy of low dose dehydroepiandrosterone (DHEA) on health-related quality of life (HRQOL) in glucocorticoid treated female patients with systemic lupus erythematosus (SLE). Forty one women (&gt;= 5 mg prednisolone/day) were included in a double-blind, randomized, placebo-controlled study for 6 months where DHEA was given at 30 mg/20 mg (&lt;= 45/&gt;= 46 years) daily, or placebo, followed by 6 months open DHEA treatment to all patients. HRQOL was assessed at baseline, 6 and 12 months, using four validated questionnaires and the patients' partners completed a questionnaire assessing mood and behaviour at 6 months. DHEA treatment increased serum levels of sulphated DHEA from subnormal to normal. The DHEA group improved in SF-36 "role emotional" and HSCL-56 total score (both p &lt; 0.05). During open DHEA treatment, the former placebo group improved in SF-36 "mental health" (p &lt; 0.05) with a tendency for improvement in HSCL-56 total score (p = 0.10). Both groups improved in McCoy's Sex Scale during active treatment (p &lt; 0.05). DHEA replacement decreased high-density lipoprotein (HDL) cholesterol and increased insulin-like growth factor I (IGF-I) and haematocrit. There were no effects on bone density or disease activity and no serious adverse events. Side effects were mild. We conclude that low dose DHEA treatment improves HRQOL with regard to mental well-being and sexuality and can be offered to women with SLE where mental distress and/or impaired sexuality constitutes a problem.},
  author       = {Nordmark, G and Bengtsson, Christine and Larsson, A and Karlsson, FA and Sturfelt, Gunnar and Ronnblom, L},
  issn         = {0891-6934},
  keyword      = {health-related quality of life,SLE,DHEA,glucocorticoid},
  language     = {eng},
  number       = {7},
  pages        = {531--540},
  publisher    = {Taylor & Francis},
  series       = {Autoimmunity},
  title        = {Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus},
  url          = {http://dx.doi.org/10.1080/08916930500285550},
  volume       = {38},
  year         = {2005},
}